Supriya Lifescience Limited (NSE:SUPRIYA)
726.20
+2.40 (0.33%)
At close: Jan 21, 2026
Supriya Lifescience Revenue
Supriya Lifescience had revenue of 2.00B INR in the quarter ending September 30, 2025, with 20.31% growth. This brings the company's revenue in the last twelve months to 7.15B, up 14.35% year-over-year. In the fiscal year ending March 31, 2025, Supriya Lifescience had annual revenue of 6.96B with 22.12% growth.
Revenue (ttm)
7.15B
Revenue Growth
+14.35%
P/S Ratio
8.18
Revenue / Employee
13.88M
Employees
515
Market Cap
58.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.96B | 1.26B | 22.12% |
| Mar 31, 2024 | 5.70B | 1.09B | 23.73% |
| Mar 31, 2023 | 4.61B | -691.11M | -13.04% |
| Mar 31, 2022 | 5.30B | 1.39B | 35.49% |
| Mar 31, 2021 | 3.91B | 712.17M | 22.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |